NASDAQ · STTK
Shattuck Labs, Inc.
$5.72-$0.09 (-1.46%)
Shattuck Labs, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.33% below the high.
Loading market information…
NASDAQ · STRO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Sutro Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.16% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Sutro Biopharma, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$1.66. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sutro Biopharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$9.10-44.44% vs estimate | $17.40M+49.83% vs estimate |
|---|
| Q4 2024 | Mar 13, 2025 | -$8.90-7.18% vs estimate | $14.80M+21.79% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -$5.90-517.8% vs estimate | $8.52M-44.28% vs estimate |
|---|
THE ANALYST VIEW
20 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $50.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.72-$0.09 (-1.46%)
Shattuck Labs, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.33% below the high.
$1.72-$0.02 (-0.87%)
InflaRx N.V.’s quoted price sits in the lower half of its reported 52-week range, 41.86% below the high.
$4.23-$0.05 (-1.05%)
Artiva Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.89% below the high.
$7.44-$0.03 (-0.4%)
Precision BioSciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.66% below the high.
$4.36$0.00 (0.0%)
Adverum Biotechnologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 28.17% below the high.
$0.86-$0.03 (-3.35%)
Pliant Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.75% below the high.
$0.84-$0.01 (-1.17%)
Connect Biopharma Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 78.13% below the high.
$2.13+$0.12 (+5.97%)
Kalaris Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 82.07% below the high.
